Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity: an OCT study

Antony Clark, Tom Wright, Maram Isaac, Carol Westall, Kamiar Mireskandari, Nasrin N. Tehrani

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This retrospective case series assessed the influence of unilateral intravitreal bevacizumab (IVB) for unilateral type 1 retinopathy of prematurity (ROP) on macular thickness and foveal development. Seven infants with unilateral type 1 ROP were treated with intravitreal bevacizumab 0.625 mg/0.025 ml in one eye only. To determine whether macular thickness and fovea structural development were affected by treatment, spectral domain optical coherence tomography was performed on both treated and untreated eyes. The mean gestational age of infants was 25.3 ± 0.3 weeks; the mean birth weight, 776 ± 17.6 g. Treatment was given at a mean postmenstrual age of 37.2 ± 0.4 weeks. Foveal development was normal in 3 (43%) treated versus 5 (71%) untreated eyes. The mean central foveal thickness for treated and untreated eyes was 270.1 μm ± 19.6 and 253.0 μm ± 27.2 respectively (P = 0.15). There was small but nonsignificant difference in foveal development and thickness in eyes treated with intravitreal bevacizumab compared to fellow eyes. This study generates important data to test the hypothesis that foveal thickness is greater in unilateral type 1 ROP eyes treated with IVB compared to untreated fellow eyes.

Original languageEnglish
Pages (from-to)499-501.e1
JournalJournal of AAPOS
Volume21
Issue number6
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Retinopathy of Prematurity
Injections
Bevacizumab
Optical Coherence Tomography
Birth Weight
Gestational Age
Therapeutics

Cite this

Clark, Antony ; Wright, Tom ; Isaac, Maram ; Westall, Carol ; Mireskandari, Kamiar ; Tehrani, Nasrin N. / Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity : an OCT study. In: Journal of AAPOS. 2017 ; Vol. 21, No. 6. pp. 499-501.e1.
@article{13076cd7768d4017a4c54b120a4e8a1f,
title = "Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity: an OCT study",
abstract = "This retrospective case series assessed the influence of unilateral intravitreal bevacizumab (IVB) for unilateral type 1 retinopathy of prematurity (ROP) on macular thickness and foveal development. Seven infants with unilateral type 1 ROP were treated with intravitreal bevacizumab 0.625 mg/0.025 ml in one eye only. To determine whether macular thickness and fovea structural development were affected by treatment, spectral domain optical coherence tomography was performed on both treated and untreated eyes. The mean gestational age of infants was 25.3 ± 0.3 weeks; the mean birth weight, 776 ± 17.6 g. Treatment was given at a mean postmenstrual age of 37.2 ± 0.4 weeks. Foveal development was normal in 3 (43{\%}) treated versus 5 (71{\%}) untreated eyes. The mean central foveal thickness for treated and untreated eyes was 270.1 μm ± 19.6 and 253.0 μm ± 27.2 respectively (P = 0.15). There was small but nonsignificant difference in foveal development and thickness in eyes treated with intravitreal bevacizumab compared to fellow eyes. This study generates important data to test the hypothesis that foveal thickness is greater in unilateral type 1 ROP eyes treated with IVB compared to untreated fellow eyes.",
author = "Antony Clark and Tom Wright and Maram Isaac and Carol Westall and Kamiar Mireskandari and Tehrani, {Nasrin N.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.jaapos.2017.06.024",
language = "English",
volume = "21",
pages = "499--501.e1",
journal = "American Association for Pediatric Opthalmology and Strabismus",
issn = "1091-8531",
publisher = "Mosby International",
number = "6",

}

Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity : an OCT study. / Clark, Antony; Wright, Tom; Isaac, Maram; Westall, Carol; Mireskandari, Kamiar; Tehrani, Nasrin N.

In: Journal of AAPOS, Vol. 21, No. 6, 01.12.2017, p. 499-501.e1.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity

T2 - an OCT study

AU - Clark, Antony

AU - Wright, Tom

AU - Isaac, Maram

AU - Westall, Carol

AU - Mireskandari, Kamiar

AU - Tehrani, Nasrin N.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - This retrospective case series assessed the influence of unilateral intravitreal bevacizumab (IVB) for unilateral type 1 retinopathy of prematurity (ROP) on macular thickness and foveal development. Seven infants with unilateral type 1 ROP were treated with intravitreal bevacizumab 0.625 mg/0.025 ml in one eye only. To determine whether macular thickness and fovea structural development were affected by treatment, spectral domain optical coherence tomography was performed on both treated and untreated eyes. The mean gestational age of infants was 25.3 ± 0.3 weeks; the mean birth weight, 776 ± 17.6 g. Treatment was given at a mean postmenstrual age of 37.2 ± 0.4 weeks. Foveal development was normal in 3 (43%) treated versus 5 (71%) untreated eyes. The mean central foveal thickness for treated and untreated eyes was 270.1 μm ± 19.6 and 253.0 μm ± 27.2 respectively (P = 0.15). There was small but nonsignificant difference in foveal development and thickness in eyes treated with intravitreal bevacizumab compared to fellow eyes. This study generates important data to test the hypothesis that foveal thickness is greater in unilateral type 1 ROP eyes treated with IVB compared to untreated fellow eyes.

AB - This retrospective case series assessed the influence of unilateral intravitreal bevacizumab (IVB) for unilateral type 1 retinopathy of prematurity (ROP) on macular thickness and foveal development. Seven infants with unilateral type 1 ROP were treated with intravitreal bevacizumab 0.625 mg/0.025 ml in one eye only. To determine whether macular thickness and fovea structural development were affected by treatment, spectral domain optical coherence tomography was performed on both treated and untreated eyes. The mean gestational age of infants was 25.3 ± 0.3 weeks; the mean birth weight, 776 ± 17.6 g. Treatment was given at a mean postmenstrual age of 37.2 ± 0.4 weeks. Foveal development was normal in 3 (43%) treated versus 5 (71%) untreated eyes. The mean central foveal thickness for treated and untreated eyes was 270.1 μm ± 19.6 and 253.0 μm ± 27.2 respectively (P = 0.15). There was small but nonsignificant difference in foveal development and thickness in eyes treated with intravitreal bevacizumab compared to fellow eyes. This study generates important data to test the hypothesis that foveal thickness is greater in unilateral type 1 ROP eyes treated with IVB compared to untreated fellow eyes.

UR - http://www.scopus.com/inward/record.url?scp=85038394457&partnerID=8YFLogxK

U2 - 10.1016/j.jaapos.2017.06.024

DO - 10.1016/j.jaapos.2017.06.024

M3 - Article

VL - 21

SP - 499-501.e1

JO - American Association for Pediatric Opthalmology and Strabismus

JF - American Association for Pediatric Opthalmology and Strabismus

SN - 1091-8531

IS - 6

ER -